OPKO Health Completes Enrollment Of 110 Test Subjects In Phase 2b Study Of OPK88003 To Treat Type 2 Diabetes And Obesity; Primary Efficacy Endpoint Is Reduction Of HbA1c Levels Over 30-Week Period
Benzinga Newsdesk